Skip to content

    Dr. Lal Path Labs Q1 FY27 earnings call

    LALPATHLAB
    Healthcare·30 Jul 2026
    Management Summary

    Dr. Lal Path Labs reported a strong Q1 FY27, with revenue growing 19.1% and PAT up 27.2%, driven by robust patient and sample volume growth and improved revenue per patient. The company expanded its test portfolio, enhanced patient experience through digital initiatives, and made strategic acquisitions in Ghana and India. Management expressed confidence in sustaining growth, with a focus on reinvestment and international expansion.

    Highlights

    7

    • Revenue grew by 19.1% YoY to ₹798 crores, marking the highest quarterly growth rate in the last 4 years.

    • EBITDA increased by 28.7% YoY to ₹247 crores, achieving a strong EBITDA margin of 31.0%.

    • Profit after tax (PAT) rose by 27.2% YoY to ₹170 crores, with a PAT margin of 21.4%.

    • Earnings per share (EPS) for Q1 FY27 increased by 27.8% to ₹10.1.

    • Patient volumes grew by 8.2% to 8.2 million, and sample volumes by 10.7% to 25.9 million.

    • Revenue per patient increased by 10% to ₹968, driven by favorable test/geography mix and CGHS/ECHS price increases.

    • Balance sheet remains strong with net cash and equivalents of ₹1,693 crores as of June 30, 2026.

    Key financials

    Single quarter

    13 metrics
    1. 01Revenue₹798 Cr+19.1%YoY
    2. 02Patient Volumes8.2 Mn+8.2%YoY
    3. 03Sample Volumes25.9 Mn+10.7%YoY
    4. 04Revenue per Patient₹968+10%YoY
    5. 05Test per Patient3.14 ratio

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Capex

    ₹140 crores

    Dividend

    ₹5/share (interim)

    M&A

    Sunshine Healthcare Limited, Ghana

    acquisition · Other · Consideration GHS 45.6 million

    M&A

    Neuome Technologies Private Limited

    acquisition · Other · Consideration ₹3.5 crores

    Liquidity

    Cash ₹1,693 crores

    Guidance & targets

    9
    CategoryTargetPriority
    Volume
    Patient Volume Growth
    mid-teens
    		Medium
    Revenue
    Revenue Growth
    mid-teens
    		Medium
    Revenue
    CGHS/ECHS Price Hike Benefit
    2%-3%
    		High
    Margin
    EBITDA Margin
    27%-28%
    		Medium
    Network Expansion
    Lab Additions
    12-15
    		High
    Network Expansion
    Radiology Centers Additions
    3-4
    		High
    Growth
    Swasthfit Growth Rate
    20% range
    		High
    International Business
    Contribution to Revenue
    beyond 5%
    		Medium
    Capex
    Annual Capex
    ₹140-150 crores
    		High

    What to watch in Q2 FY27

    5

    Patient Volume Growth Trajectory

    next quarter (post Q2 FY27)
    Current8.2% in Q1 FY27
    TargetClarity on full-year outlook post Q2

    Why it matters

    Management indicated Q2 results are needed to assess if Q1's strong volume growth is sustainable or if shifts between quarters are at play.

    I think once we are through Q2 as well, when we have done half the year, we might be in a better position to talk about what the outlook for the year could be more comfortably.

    Risks & concerns

    3
    RiskSeverity

    Competitive intensity in the diagnostics industry

    Competition has always been intense and is likely to remain so; management does not expect it to reduce. — Management acknowledged

    medium

    Impact of weather patterns on diagnostic testing

    Q1 saw different weather patterns than usual, but the impact on diagnostic testing is currently unknown and requires more data from Q2. — Management not addressed

    low

    Geopolitical issues, currency, and inflation affecting material costs

    Currently, material costs are manageable due to stepped-up purchases, but continued geopolitical issues could impact imported material costs. — Management acknowledged

    low

    Q&A highlights

    8

    “The CGHS, ECHS price increase is now flowing through into the system. Our assessment is that it kind of is to the tune of between 2%-3% at an overall company level. And I think this benefit will continue for at least another 2-3 quarters.”

    Provides a specific quantification of a key driver for revenue per patient growth and its expected duration.

    asked by Amey Chalke

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Q1 FY27 Performance and Growth Drivers

    Dr. Lal Path Labs reported a robust Q1 FY27, with revenue reaching ₹798 crores, a 19.1% year-on-year growth, marking the highest quarterly growth in the last four years. This performance was primarily driven by an 8.2% increase in patient volumes to 8.2 million and a 10.7% rise in sample volumes to 25.9 million. Revenue per patient also saw a significant 10% increase to ₹968, attributed to a favorable test and geography mix, alongside price adjustments from CGHS and ECHS.

    02

    Profitability Expansion

    The company demonstrated strong profitability, with EBITDA growing 28.7% year-on-year to ₹247 crores, resulting in an EBITDA margin of 31.0%. Profit Before Tax (PBT) increased by 26.3% to ₹229 crores, and Profit After Tax (PAT) grew by 27.2% to ₹170 crores, achieving a PAT margin of 21.4%. Earnings per share (EPS) also saw a healthy increase of 27.8% to ₹10.1 for the quarter.

    03

    Strategic Acquisitions and International Expansion

    Dr. Lal Path Labs expanded its footprint through two strategic acquisitions. It acquired an 80% equity stake in Sunshine Healthcare Limited, Ghana, for a consideration not exceeding GHS 45.6 million, marking a first step in extending diagnostic expertise outside India. Additionally, the company acquired a 30% equity stake in Neuome Technologies Private Limited for up to ₹3.5 crores, focusing on innovative solutions in sample preservation and biobanking to strengthen healthcare innovation and operational efficiency.

    04

    Product Innovation and Digital Initiatives

    The company launched 116 new tests in Q1 FY27, including four first-in-India tests, expanding its advanced diagnostics portfolio with offerings like NGS Chimerism and AI-enabled Histopathology. To enhance patient experience, Dr. Lal Path Labs introduced a GenAI Patient Bot on WhatsApp (SwasthAI), enabling conversational transactions for test inquiries, prescription uploads, and report access. Operational excellence was also highlighted with industry-leading turnaround times, including 3 hours for 90% of routine walk-in tests.

    05

    Capital Allocation and Future Outlook

    With net cash and equivalents of ₹1,693 crores, the company plans to utilize this liquidity primarily for M&A activities, particularly in underserved regions of India (West & South), and for rolling out high-end radiology centers in Delhi NCR and other Tier 2 markets in North. The planned annual capex for this year and next is approximately ₹140-150 crores. An interim dividend of 50% (₹5 per share) was also declared. Management expects revenue growth to be in the mid-teens for FY27, with a focus on reinvesting for future growth.

    06

    Rural Outreach Program and Swasthfit Performance

    The rural outreach program, active in 7 states, tested over 110,000 patients in Q1 FY27, focusing on providing quality diagnostics for non-communicable diseases in underserved regions. This program is distinct from Swasthfit, which continues to show strong traction, growing in the 20% range and contributing 27% to overall revenues. Management expects Swasthfit's growth rate to be sustainable for some time.

    This is an AI-generated summary of a publicly available earnings call transcript.